Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer

Abstract Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in "castration syndrome",...

Full description

Saved in:
Bibliographic Details
Published in:South Asian journal of cancer 2015-04, Vol.4 (2), p.095-097
Main Author: Ali Shah, Syed Imran
Format: Article
Language:English
Subjects:
Androgen deprivation therapy
parenteral estrogen
prostate cancer
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER
TRENDS IN HORMONAL THERAPY IN PROSTATE CANCER: Review Article
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Androgen deprivation therapy (ADT) is a key management strategy for prostate cancer (PC), achieved commonly by administration of luteinizing hormone-releasing hormone agonist (LHRHa), ADT markedly suppresses both male and female sex hormones which results in "castration syndrome", a constellation of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and fractures. Recent evidence suggests that estrogen, in the parenteral form, may emerge as an alternative to LHRHa as it offers potential benefits of arresting PC growth as well as avoiding some of the estrogen deficiency related toxicities of LHRHa by maintaining endogenous levels of estrogen.
ISSN:2278-330X
2278-4306
DOI:10.4103/2278-330X.155699